Key result
APOC3 -455C variant linked to higher CAD risk in metabolic syndrome despite ~13% lower obesity rates.
Why the study?
The contribution of apolipoprotein C-III levels and APOC3 T-455C polymorphisms to coronary artery disease risk in metabolic syndrome patients was unclear.
Do apoC-III levels and the APOC3 T-455C polymorphism correlate with the risk of coronary artery disease in patients with metabolic syndrome?
Population
873 patients including 549 with CAD and 251 with normal coronary arteries, 270 with metabolic syndrome
Comparison
Higher apoC-III levels and APOC3 T-455C polymorphism carriers vs lower apoC-III levels and non-carriers
Design
Observational cross-sectional study
Authors
Loading...
Elevated apoC-III and −455C variant were associated with CAD in metabolic syndrome; hypothesis-generating for risk stratification, prospective studies needed.
Observational (n=873)
Do apoC-III levels and the APOC3 T-455C polymorphism correlate with the risk of coronary artery disease in patients with metabolic syndrome?
ApoC-III levels and the APOC3 T-455C polymorphism are significantly associated with an increased risk of coronary artery disease in patients with metabolic syndrome.
Olivieri et al. (2003) conducted an observational in Coronary artery disease and metabolic syndrome (n=873). APOC3 T-455C polymorphism and apoC-III levels vs. Noncarriers and lower apoC-III levels was evaluated on Probability of coronary artery disease. The APOC3 -455C variant increased CAD probability in metabolic syndrome, though obesity was less frequent in MS carriers of the -455C allele than noncarriers (21.6% vs. 34.8%, P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: